Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial

Jinyoung Kim, Kyoung Min Kim, Soo Lim, Moo Il Kang, Ki Hyun Baek, Yong Ki Min

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The co-occurrence of diabetes and osteoporosis is common in postmenopausal women. For the treatment of postmenopausal osteoporosis, current guidelines recommend initial treatment with bisphosphonates, but it is unclear whether bisphosphonates provide a similar degree of therapeutic efficacy in patients with diabetes. This study sought to compare the efficacy of monthly oral ibandronate for retaining bone mineral density (BMD) in diabetic and non-diabetic postmenopausal women with osteoporosis. Methods: Postmenopausal osteoporotic women with or without diabetes were enrolled in this study from three hospitals in an open-label approach from 2018 to 2020. Each group of patients received oral ibandronate 150 mg once monthly for 1 year. BMD, trabecular bone score (TBS), serum C-terminal telopeptide of type I collagen (CTx) and procollagen type 1 N-terminal propeptide (P1NP) were evaluated prospectively. Treatment-emergent adverse events and changes in glucose metabolism during drug use were also monitored. Results: Among the 120 study participants, 104 (86.7%) completed the study. Following 1 year of treatment, BMD increased by 3.41% vs. 3.71% in the lumbar spine, 1.30% vs. 1.18% in the femur neck, and 1.51% vs. 1.58% in the total hip in the non-diabetes and diabetes groups, respectively. There were no significant differences in BMD changes between the groups, and the differences in CTx or P1NP changes between groups were not significant. We did not observe any significant differences in baseline TBS values or the degree of change between before and after 1 year of ibandronate treatment in either group in this study. A total of 11 adverse events (9.2%) that recovered without sequelae occurred among the 120 included patients, and there was no significant difference in the frequency of adverse events between the groups (p = 0.862). The changes in fasting glucose and glycated hemoglobin levels between before and after treatment were not significant in the diabetic group. Conclusions: Bisphosphonate therapy showed similar increases in BMD and decreases in CTx and P1NP of postmenopausal women with and without diabetes. Monthly oral ibandronate can be a safe and effective therapeutic option in postmenopausal osteoporosis patients with type 2 diabetes. Trial registration: NCT number: NCT05266261, Date of registration: 04 March 2022.

Original languageEnglish
Article number99
JournalBMC Endocrine Disorders
Volume22
Issue number1
DOIs
StatePublished - Dec 2022
Externally publishedYes

Keywords

  • Bisphosphonates
  • Osteoporosis
  • Type 2 diabetes mellitus

Fingerprint

Dive into the research topics of 'Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial'. Together they form a unique fingerprint.

Cite this